Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lihui Nie

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
Infection and Drug Resistance|January 20, 2025
Contezolid Harbored Equivalent Efficacy to Linezolid in Tuberculosis Treatment in a Prospective and Randomized Early Bactericidal Activity StudyGuanglu Jiang, Rongmei Liu, Yi Xue, et al.
Iscience|June 15, 2026
A multi-center clinical evaluation on first-in-class ROP-based IGRA for tuberculosis diagnosisQiang Li, Yulin Huang, Lihui Nie, et al.
The Journal of Infection|April 1, 2023
Systemic immune dysregulation in severe tuberculosis patients revealed by a single-cell transcriptome atlasYi Wang, Qing Sun, Yun Zhang, et al.
BMC Medicine|October 15, 2024
Correction: Nine months of bedaquiline, linezolid, levofloxacin, clofazimine, and cycloserine chemotherapy for rifampicin/multidrug-resistant tuberculosis: a multicenter, randomized, open-label non-inferiority trial in ChinaYanhua Song, Wei Shu, Yi Pei, et al.
BMC Medicine|September 19, 2024
Nine months of bedaquiline, linezolid, levofloxacin, clofazimine, and cycloserine chemotherapy for rifampicin/multidrug-resistant tuberculosis: a multicenter, randomized, open-label non-inferiority trial in ChinaYanhua Song, Wei Shu, Yi Pei, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
Infection and Drug Resistance|January 20, 2025
Contezolid Harbored Equivalent Efficacy to Linezolid in Tuberculosis Treatment in a Prospective and Randomized Early Bactericidal Activity StudyGuanglu Jiang, Rongmei Liu, Yi Xue, et al.
Iscience|June 15, 2026
A multi-center clinical evaluation on first-in-class ROP-based IGRA for tuberculosis diagnosisQiang Li, Yulin Huang, Lihui Nie, et al.
The Journal of Infection|April 1, 2023
Systemic immune dysregulation in severe tuberculosis patients revealed by a single-cell transcriptome atlasYi Wang, Qing Sun, Yun Zhang, et al.
BMC Medicine|October 15, 2024
Correction: Nine months of bedaquiline, linezolid, levofloxacin, clofazimine, and cycloserine chemotherapy for rifampicin/multidrug-resistant tuberculosis: a multicenter, randomized, open-label non-inferiority trial in ChinaYanhua Song, Wei Shu, Yi Pei, et al.
BMC Medicine|September 19, 2024
Nine months of bedaquiline, linezolid, levofloxacin, clofazimine, and cycloserine chemotherapy for rifampicin/multidrug-resistant tuberculosis: a multicenter, randomized, open-label non-inferiority trial in ChinaYanhua Song, Wei Shu, Yi Pei, et al.
Pageof 2